NCT00590447
Risk Stratified Sequential Treatment for CD20-positive PTLD treatment 2 completed NCT02042391
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy treatment 2 completed NCT05453396
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies treatment 2 recruiting NCT01748721
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma treatment 1 completed NCT04507477
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial prevention 1 / 2 unknown_status NCT03386539
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score treatment 3 active_not_recruiting NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT01815749
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma No drug interventions treatment 1 active_not_recruiting NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas treatment 1 / 2 terminated NCT01254578
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers treatment 1 completed NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma treatment 2 completed NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma treatment 1 completed NCT01116154
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma treatment 1 terminated NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy treatment 1 completed NCT00354185
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma treatment 1 terminated NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant treatment 1 / 2 completed NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies treatment Not Available completed NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer treatment 1 / 2 completed NCT04337827
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder treatment 2 terminated NCT02763254
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas treatment 2 terminated NCT02652715
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma No drug interventions basic_science Not Available completed NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT01434472
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma treatment 2 terminated NCT01261247
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma treatment 2 completed NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Not Available Not Available completed NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors treatment 1 completed NCT01075321
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma treatment 1 / 2 completed NCT00918333
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma treatment 1 / 2 completed NCT00348985
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas treatment 1 completed NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer treatment Not Available completed NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT00064246
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder treatment 1 / 2 completed NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer treatment 2 completed NCT00036855
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma treatment 1 terminated NCT06040320
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) treatment 1 / 2 recruiting NCT04189835
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients No drug interventions Not Available Not Available recruiting NCT03546101
Early Detection of Epstein-Barr Virus Related Disease. No drug interventions Not Available Not Available completed NCT03086395
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) treatment 2 withdrawn NCT02580539
A Study of the Safety and Efficacy of EBV Specific T-cell Lines No drug interventions treatment 1 / 2 recruiting NCT02153580
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia treatment 1 active_not_recruiting NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies supportive_care 2 completed NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 withdrawn NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies treatment 2 completed NCT01231919
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia No drug interventions treatment 1 completed NCT01129180
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma treatment 1 completed NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer No drug interventions supportive_care Not Available completed NCT00867529
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma treatment 2 completed NCT01760226
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies treatment 0 completed NCT05688241
EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases No drug interventions treatment 1 / 2 not_yet_recruiting NCT01088724
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) treatment 4 completed NCT04138875
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) treatment 2 withdrawn NCT06422715
PTLD: Multicentric Retrospective Study No drug interventions Not Available Not Available not_yet_recruiting NCT05258136
Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV No drug interventions treatment Not Available unknown_status NCT02318030
CNTRP POSITIVE Study No drug interventions Not Available Not Available completed NCT03131934
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant treatment 0 active_not_recruiting NCT01058239
Bortezomib Plus Rituximab for EBV+ PTLD treatment 2 completed NCT01964755
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma treatment 2 terminated NCT01458548
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD) treatment 2 terminated NCT02984215
aCGH Impacts Survival in Plasma Cell PTLD No drug interventions Not Available Not Available completed NCT06666153
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases No drug interventions treatment 1 not_yet_recruiting NCT02182986
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children No drug interventions Not Available Not Available completed